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Despite the belief that the etiology of and risk factors for rectal cancer might differ from those for colon cancer,
relatively few studies have examined rectal cancer in relation to use of nonsteroidal antiinflammatory drugs
(NSAIDs). The authors evaluated the association between NSAIDs and distal large bowel cancer in African
Americans and whites, using data from a population-based case-control study of 1,057 incident cases of adeno-
carcinoma of the sigmoid colon, rectosigmoid junction, and rectum and 1,019 controls from North Carolina (2001–
2006). NSAID use was inversely associated with distal large bowel cancer in whites (odds ratio (OR) ¼ 0.60, 95%
confidence interval (CI): 0.46, 0.79). The inverse association was evident for all types of NSAIDs but was slightly
stronger with prescription NSAIDs, particularly selective cyclooxygenase 2 inhibitors (OR ¼ 0.38, 95% CI: 0.25,
0.56). Compared with whites, a relatively weak inverse association was found in African Americans (OR ¼ 0.87,
95% CI: 0.55, 1.40), although odds ratio heterogeneity by race could not be confirmed (P ¼ 0.21). In addition, the
strength of the association with NSAIDs varied by tumor location, suggesting more potent effects for rectal and
rectosigmoid cancers than for sigmoid cancer. The chemopreventive potential of NSAIDs might differ by population
and by tumor characteristics.
anti-inflammatory agents, non-steroidal; colonic neoplasms; colorectal neoplasms; intestine, large; population
groups; rectal neoplasms
Abbreviations: CI, confidence interval; COX-2, cyclooxygenase 2; NSAID, nonsteroidal antiinflammatory drug; OR, odds ratio.
The inverse association between nonsteroidal antiinflam-
matory drugs (NSAIDs) and colorectal cancer has been well
documented (1–13); however, relatively few studies have
focused specifically on rectal cancer, despite the belief that
the etiology of and risk factors for rectal cancer might differ
from those for colon cancer. The proximal and distal parts of
the large bowel have different embryonic origins, as well as
physiologic differences in bile salt concentration and bacte-
rial populations (14). Different genetic aberrations have
been associated with cancers arising at different subsites
of the large bowel (15). Moreover, although the anatomic
distribution of colorectal cancer has been shown to differ
between African Americans and whites (16, 17), there have
been few studies of risk factors for colorectal cancer in
African Americans. We therefore examined the association
between NSAIDs and adenocarcinoma of the distal large
bowel (i.e., sigmoid colon, rectosigmoid junction, and rec-
tum) in African Americans and whites.
MATERIALS AND METHODS
We used data from phase 2 of the North Carolina Colon
Cancer Study. North Carolina Colon Cancer Study II is
a population-based case-control study in 33 counties in the
central and eastern part ofNorthCarolina. BetweenOctober 1,
2001, and May 31, 2006, patients with a first diagnosis of
invasive adenocarcinoma of the sigmoid colon, rectosigmoid
junction, or rectum were identified through the rapid ascer-
tainment system of the North Carolina Central Cancer
Registry. The procedure for case ascertainment and its
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effectiveness has been described in detail elsewhere (18).
Cases were eligible for the study if they were residents of
the selected counties, aged 40–80 years, and African Ameri-
can or white; if they had a North Carolina driver’s license or
identification card; and if they were able to complete an in-
terview in English. A total of 1,831 potentially eligible cases
were identified; of these, 57 (3%)were excluded for physician
refusal and 357 (19%) were subsequently found to be ineligi-
ble. Of the remaining 1,417 eligible cases, 118 (8%) could not
be contacted, 242 (17%) refused to participate, and 1,057
(75%) completed an in-person interview.
Controls were randomly selected from North Carolina
Division of Motor Vehicle records, based on sampling prob-
abilities within blocks defined by 5-year age group, sex, and
race, using the technique of randomized recruitment (19).
Initially, 2,345 subjects who were free of cancer were iden-
tified as potentially eligible controls, but 518 (22%) were
later determined to be ineligible. Of the 1,827 eligible
controls, 325 (18%) could not be contacted and 483 (26%)
refused to participate. A total of 1,019 (56% of eligible
controls) completed an interview. The final data set for analy-
sis included 1,057 cases and 1,019 controls.
The study was approved by the institutional review board
at the University of North Carolina School of Medicine, and
all subjects provided written informed consent.
Data collection
In-person interviews were conducted in each subject’s
home or at another convenient location by trained nurse
interviewers using a standard questionnaire. The question-
naire included information regarding demographic charac-
teristics, socioeconomic indicators (such as years of
education, income level, and occupation history), medica-
tion use, medical history, family history of cancer, smoking
habits, and weight 1 year prior to diagnosis (for cases) or
interview (for controls). Current weight and height at the
time of interview were also measured. Subjects were asked
about type and duration of various activities engaged in on
typical week/working and weekend/nonworking days. Then
the energy expenditure involved in each activity was re-
trieved from the Compendium of Physical Activities (20).
Metabolic equivalents were calculated by multiplying the
number of hours spent in these activities, the number of
metabolic equivalents for the category, and body weight
(20). Dietary intake was assessed with the Diet History
Questionnaire, which was developed and evaluated at the
National Cancer Institute (21). Cancer stage (local, regional,
distant, or unknown), tumor location (sigmoid colon, recto-
sigmoid junction, or rectum), and other diagnosis-related
data were available from the Central Cancer Registry.
Assessment of NSAID use
We assessed use of NSAIDs during the past 5 years (for
controls) and for the 5 years prior to diagnosis (for cases). For
the purpose of data collection, NSAIDs were classified into 4
categories: 1) over-the-counter aspirin (e.g, Bufferin, Anacin,
Excedrin, BC Powder or Goody’s Powder, Alka-Seltzer, or
generic equivalents); 2) over-the-counter nonaspirin NSAID
pain medications (e.g., Advil, Motrin, Aleve, or generic
equivalents); 3) prescription selective cyclooxygenase
2 (COX-2) inhibitors (e.g., Vioxx, Celebrex, or generic
equivalents); and 4) prescription nonselective NSAID
pain medications (e.g., Motrin, Daypro, Naprosyn, Feldene,
or generic equivalents). For each NSAID category, respond-
ents who reported ever use of NSAIDs were asked about
frequency of use, duration of use, and use 1 year prior to
diagnosis (for cases) or interview (for controls). Participants
were queried separately about their use of acetaminophen
or Tylenol, which is an antipyretic and analgesic with very
weak antiinflammatory activity (22). Acetaminophen was not
classified as an NSAID in these analyses. (The names and
locations of the manufacturers of all brand-name products
in this paper are given in the Appendix Table.)
Statistical analysis
We stratified study participants by race to compare distri-
butions of selected characteristics between cases and controls.
Odds ratios and 95% confidence intervals for the association
between NSAID use and distal large bowel cancer were esti-
mated from unconditional logistic regression models in all
subjects and in race-specific models. For all analyses, the
referent group consisted of subjects who reported never use
of any NSAIDs in the past 5 years. Subjects who had used any
of the NSAIDs queried about in the past 5 years were defined
as ever users. We also examined recent use (defined as use of
any NSAIDs in the past year or none) and average monthly
dose in the past 5 years (categorized as use <15 times per
month or 15 times per month over the past 5 years). In
addition, we assessed use of different types of NSAIDs
(over-the-counter aspirin only, over-the-counter nonaspirin
NSAIDs only, prescription selective COX-2 inhibitors, or
other prescription nonselective NSAIDs) in relation to distal
large bowel cancer, with participants classified as regular
users of specific types of NSAIDs if they had taken them at
least 3 times per week for 3 months or more.
All logistic regression models included age (continuous),
sex, race, and an offset term to adjust for sampling probability.
Other potential covariates assessed for inclusion in multivari-
able models were: years of education (<12, 12–15, or 16
years), annual household income (<$15,000, $15,000–
$24,999, $25,000–$49,999, or $50,000), smoking status
(current, past, or never smoker) at the time of diagnosis (for
cases) or interview (for controls), family history of colorectal
cancer (having had at least 1 first-degree relative with colorec-
tal cancer or not), comorbidity (having at least 1 of the follow-
ing conditions: arthritis, hypertension, heart attack, or diabetes
mellitus) prior to diagnosis (for cases) or at the time of inter-
view (for controls), bodymass index (weight (kg)/height (m)2)
1 year prior (<25 (normal or underweight), 25–29.9 (over-
weight), or30 (obese)), physical activity 1 year prior (tertiles
based on the distribution among controls), ever use of calcium
supplements during the past 5 years (yes or no), and dietary
intakes of energy and fat during the past year (tertiles based on
the distributions among controls). To determine which cova-
riates should be entered into the final multivariable models, we
constructed full models by race with all potential confounders
and assessed the change in race-specific b coefficients for ever
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use versus never use of any NSAIDs in relation to distal large
bowel cancer when covariates were removed. Only body mass
index 1 year prior and calciumsupplement use resulted inmore
than a 10% change in the b coefficient among whites, whereas
physical activity 1 year prior, total energy intake, and dietary
fat intake, as well as body mass index 1 year prior and calcium
supplement use, were found to yield more than a 10% change
in theb coefficient amongAfricanAmericans. For consistency,
we included the same set of covariates (age, sex, race, sampling
probability, physical activity 1 year prior, ever use of calcium
supplements, total energy intake, dietary fat intake, and body
mass index 1 year prior) in the finalmultivariablemodels for all
subjects and in race-specific models.
Likelihood ratio tests comparing models with and without
multiplicative interaction terms between NSAID use and
race were used to assess odds ratio modification (statistical
interaction) in the association. We used multinomial logistic
regression to simultaneously estimate odds ratios and 95%
confidence intervals for sigmoid, rectosigmoid, and rectal
cancers in comparison with controls. Wald statistics were
used to assess statistical heterogeneity among the 3 subsite-
specific effect estimates. Analyses were performed using






No. % No. % No. % No. %
Total 790 841 267 178
Location of tumor
Sigmoid colon 304 38.5 100 37.5 0.014b
Rectosigmoid junction 143 18.1 30 11.2
Rectum 343 43.4 137 51.3
Age, years
40–49 111 14.1 80 9.5 0.003 40 15.0 21 11.8 0.35
50–59 212 26.8 195 23.2 77 28.8 45 25.3
60–69 230 29.1 268 31.9 89 33.3 59 33.2
70–79 237 30 298 35.4 61 22.9 53 29.8
Median age, years 60 64 59 63
Sex
Male 457 57.9 509 60.5 0.272 140 52.4 92 51.7 0.877
Female 333 42.2 332 39.5 127 47.6 86 48.3
Years of education
<12 124 16.2 81 9.8 0.000 77 30.1 40 23.1 0.28
12–15 420 55.0 403 48.9 132 51.6 97 56.1
16 220 28.8 340 41.3 47 18.4 36 20.8
Annual household income
$15,000 93 12.8 79 10.1 0.158 85 37.6 60 38.7 0.976
$15,000–$24,999 123 16.9 120 15.4 42 18.6 26 16.8
$25,000–$49,999 192 26.5 200 25.6 47 20.8 33 21.3
$50,000 318 43.8 382 48.9 52 23.0 36 23.2
Smoking status
Never smoker 285 37.4 309 37.8 0.509 98 38.3 75 43.4 0.173
Past smoker 357 46.8 396 48.4 94 36.7 68 39.3
Current smoker 121 15.9 113 13.8 64 25.0 30 17.3
Family history of colorectal cancerc
Yes 103 18.5 93 15.0 0.103 33 18.3 11 8.6 0.016
No 454 81.5 529 85.1 147 81.7 117 91.4
Underwent sigmoidoscopy or
colonoscopy in the past 10 years
Yes 169 22.1 533 64.7 0.000 50 19.8 91 54.2 0.000
No 595 77.9 291 35.3 202 80.2 77 45.8
Table continues
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Stata 9.2 (Stata Corporation, College Station, Texas), and all
statistical tests were 2-sided, with an a level of 0.05.
RESULTS
The study consisted of 1,631 white participants (790
cases and 841 controls) and 445 African-American partic-
ipants (267 cases and 178 controls) (Table 1). The propor-
tion of patients with rectal cancer was higher among
African-American cases than among white cases (51.3%
vs. 43.4%; P ¼ 0.014). In both racial groups, cases were
younger, were less educated, and more often reported hav-
ing a family member with colorectal cancer than controls,
but far fewer had obtained colorectal cancer screening.
Cases also had higher intakes of energy and dietary fat
and tended to have higher body mass indexes. A greater
percentage of controls than of cases reported ever use of
calcium supplements in the past 5 years, whereas subjects
who reported current smoking were less common among
controls than among cases, particularly for African Ameri-
cans (25% in cases vs. 17% in controls).
Approximately 76% of cases and 83% of controls re-
ported ever use of any NSAIDs in the past 5 years (Table
2). Overall, compared with never use, ever use of NSAIDs
was inversely associated with distal large bowel cancer
(multivariable odds ratio (OR) ¼ 0.66, 95% confidence in-
terval (CI): 0.52, 0.83) after adjustment for age, sex, race,
body mass index, level of physical activity, ever use of
calcium supplements, total energy intake, dietary fat intake,
and sampling probability. The strength of the association
with ever use of NSAIDs was similar for recent use and







No. % No. % No. % No. %
Comorbid conditiond
Yes 525 84.4 607 85.6 0.537 198 95.2 146 94.2 0.673
No 97 15.6 102 14.4 10 4.8 9 5.8
Body mass indexe
<25 177 24.1 254 31.7 0.000 49 20.3 34 20.4 0.474
25–29.9 278 37.8 325 40.5 75 31.1 61 36.5
30 281 38.2 223 27.8 117 48.6 72 43.1
Median body mass index 28.1 26.9 29.8 29.1
Calcium supplement use
Yes 264 34.8 375 45.7 0.000 69 27.1 55 32.0 0.272
No 495 65.2 446 54.3 186 72.9 117 68.0
Physical activity level, average
metabolic equivalent-minutes/dayf
First tertile (<1,882) 243 33.2 260 32.8 0.208 93 38.8 57 34.6 0.041
Second tertile (1,882–2,077) 212 29.0 260 32.8 61 25.4 61 37.0
Third tertile (2,078) 277 37.8 272 34.3 86 35.8 47 28.5
Median physical activity level 1,968.6 1,974 1,938.9 1,920.9
Total energy intake, kcal/dayf
First tertile (<1,711) 220 28.3 277 33.1 0.004 72 28.2 60 34.7 0.117
Second tertile (1,711–2,413) 246 31.7 292 34.8 57 22.4 45 26.0
Third tertile (2,414) 311 40.0 269 32.1 126 49.4 68 39.3
Median energy intake 2,142.1 1,992.3 2,405.3 2,139.6
Dietary fat intake, g/dayf
First tertile (<64) 203 26.1 273 32.6 0.000 70 27.5 57 33.0 0.457
Second tertile (64–97) 259 33.3 302 36.0 72 28.2 47 27.2
Third tertile (98) 315 40.5 263 31.4 113 44.3 69 40.0
Median dietary fat intake 86.7 78.9 86.7 80.0
a P values were based on chi-square tests.
b P value for comparison between race and tumor location.
c Having a first-degree relative diagnosed with colorectal cancer.
d Having at least 1 of the following conditions: arthritis, hypertension, heart attack or heart problems, or diabetes mellitus.
e Weight (kg)/height (m)2.
f Tertiles were based on the distribution among controls.
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use of NSAIDs in the past 5 years. All categories of NSAIDs
were inversely associated with distal large bowel cancer, but
the inverse associations were slightly stronger for prescrip-
tion NSAIDs than for nonprescription NSAIDs, particularly
selective COX-2 inhibitors (multivariable OR ¼ 0.44, 95%
CI: 0.31, 0.63).
When results were stratified by race, the association be-
tween NSAIDs and distal large bowel cancer remained
strongly protective in whites, but there was less evidence
of an association among African Americans (for ever use vs.
never use: OR ¼ 0.87, 95% CI: 0.55, 1.40) (Table 3). Over-
the-counter aspirin and prescription COX-2 inhibitors were
inversely associated with distal large bowel cancer among
African Americans, but the magnitudes of the associations
were weaker than those for whites (among African Ameri-
cans, OR ¼ 0.87 (95% CI: 0.50, 1.52) for aspirin and
OR ¼ 0.69 (95% CI: 0.29, 1.61) for COX-2 inhibitors).
The likelihood ratio test P value comparing models with
and without multiplicative interaction terms between race
and ever use of any NSAIDs was 0.21.
We also examined the possibility that the association with
NSAID use might differ by tumor location (Table 4). In
general, NSAID use was inversely associated with all sub-
sites of distal large bowel cancer; however, the inverse as-
sociation for NSAID use tended to be more pronounced for
rectal and rectosigmoid cancer than for sigmoid cancer. The
multivariable odds ratios associated with ever use of
NSAIDs were 0.60 (95% CI: 0.44, 0.81) for rectal cancer
and 0.50 (95% CI: 0.33, 0.74) for rectosigmoid cancer,
while the multivariable odds ratio for sigmoid cancer was
0.81 (95% CI: 0.60, 1.09) (Wald test for equality of coef-
ficients: P ¼ 0.05). Aweaker association with sigmoid can-
cer than with rectal and rectosigmoid cancer was evident in
both African Americans and whites (data not shown).
DISCUSSION
We found that NSAID use was inversely associated with
distal large bowel cancer in whites. Among whites, the in-
verse association was evident for all types of NSAIDs eval-
uated but was slightly stronger with prescription NSAIDs,
particularly with selective COX-2 inhibitors, than with non-
prescription NSAIDs. The strengths of the associations
among whites were similar for more recent use, higher av-
erage monthly use, and ever use. On the other hand, we
observed a relatively weak association with NSAID use in
African Americans, although the test for odds ratio hetero-
geneity between racial groups was not statistically signifi-
cant (P ¼ 0.21). We also observed that inverse associations
with NSAID use were stronger for rectal and rectosigmoid
cancer than for sigmoid cancer.
The exact mechanism of the association between NSAIDs
and colorectal cancer remains unclear; however, antineo-
plastic properties of NSAIDs are largely attributed to inhi-
bition of cyclooxygenase enzymes, particularly COX-2
(23). COX-2 is an inducible form of cyclooxygenase that
is expressed in response to proinflammatory and mitogenic
stimuli (24, 25). Several investigators have reported higher
expression of COX-2 in colon cancer samples than in nor-
mal colon tissue (26). NSAIDs suppress COX-2-induced
angiogenesis and resistance to apoptosis in experimental
studies (27), and aspirin has been associated with a reduced
risk of colorectal adenoma, a precursor to colorectal cancer
in randomized clinical studies (28, 29).
Our results in whites are consistent with previous epide-
miologic research that has shown that persons taking aspi-
rin/NSAIDs regularly (2–3 times per week) had a lower risk
of colorectal cancer than thosewhowere not (1–13). It has also
been suggested that protection from aspirin increases with
a higher dosage (30). Negative findings from 2 randomized
clinical trials in which participants were treated with 325 mg
(31) or 100 mg (32) of aspirin on alternate days were partly
attributed to the low doses of NSAIDs used in the interven-
tions, which were lower than the dose used to define ‘‘regular
users’’ in most observational epidemiologic studies (31). For
each category of NSAIDs, we defined regular users as those
who used the correspondingNSAIDs at least 3 times per week,
and we assessed different types of NSAIDs in relation to distal
large bowel cancer.We observed a slightly stronger association
with prescription NSAIDs relative to over-the-counter NSAIDs.
Given that the dose of prescription NSAIDs is generally higher
than the dose of nonprescription NSAIDs (33), our result is
consistent with the previous findings that higher doses of
NSAIDsmay bemore effective in preventing colorectal cancer.
Sansbury et al. (34) previously reported inverse associa-
tions of NSAIDswith colon cancer in bothAfricanAmericans
and whites in the same study counties during 1996–2000. In
contrast, in the present study, we found a relatively weak in-
verse association between NSAIDs and distal large bowel
cancer in African Americans compared with whites, although
race-specific effect estimates did not provide clear evidence of
odds ratio heterogeneity between the 2 racial groups.
Several explanations are possible for the weak association
between NSAIDs and distal large bowel cancer in African
Americans in the current study. First, there could be mis-
classification due to differential patterns of NSAID use be-
tween African Americans and whites. It is possible that
African-American users might have taken NSAIDs less fre-
quently than white NSAID users. To rule out this possibility,
we compared the average monthly dose over the past 5 years
between African-American and white NSAID users.
Whereas African-American NSAID users, in fact, had a sig-
nificantly lower average monthly dose (mean ¼ 14.1 uses)
compared with white NSAID users (mean ¼ 20.5 uses;
P < 0.01), the racial difference in average monthly dose
would not fully explain a weaker association in African
Americans compared with whites, since there was no in-
verse association even among African Americans with av-
erage monthly use of 15 or higher in the past 5 years.
We also hypothesized that the specific types of NSAIDs
used and the resulting potency or dose of NSAIDs used might
have differed by race. Since data on the specific types of
NSAIDs taken were not collected for the current study, we
indirectly tested this hypothesis using data from phase 1 of the
North Carolina Colon Cancer Study, which employed 21 sep-
arate questions (12 for prescription NSAIDs and 9 for over-
the-counter NSAIDs) to query about use of specific products.
This additional analysis showed that certain NSAID products
(BC,Goody’s, or Stanback powder or tablets andAlka-Seltzer
or Bromo Seltzer) or their generic equivalents were twice as
1296 Kim et al.
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commonly used by African Americans as by whites. How-
ever, despite these differences, Sansbury et al. (34) observed
an inverse association between NSAIDs and colon cancer
among African Americans in North Carolina Colon Cancer
Study I; consequently, it seems unlikely that differential use of
these products would explain the weak association between
Table 3. Odds Ratios for the Association Between Use of Nonsteroidal Antiinflammatory Drugs and Distal Large Bowel Cancer, by Race, North








No. % No. % No. % No. %
Never use (referent) 174 22.8 124 15.1 1.00 74 28.9 45 26.2 1.00
Ever use 590 77.2 700 85.0 0.60 0.46, 0.79 182 71.1 127 73.8 0.87 0.55, 1.40
Recent useb 530 69.4 658 79.9 0.57 0.43, 0.75 158 61.7 117 68.0 0.82 0.50, 1.32
Average monthly use
in the past 5 years,
no. of times
<15 325 42.5 326 39.6 0.65 0.49, 0.88 121 47.3 89 51.7 0.78 0.47, 1.29





280 36.7 385 46.7 0.56 0.41, 0.75 75 29.2 54 31.4 0.87 0.50, 1.52
Over-the-counter,
nonaspirin NSAIDs
89 11.7 100 12.1 0.57 0.39, 0.84 30 11.7 10 5.8 1.93 0.81, 4.56
Prescription nonselective
NSAIDs
48 6.3 73 8.9 0.48 0.30, 0.75 18 7.0 8 4.7 1.17 0.44, 3.07
Selective COX-2 inhibitors 69 9.0 119 14.4 0.38 0.25, 0.56 18 7.0 16 9.3 0.69 0.29, 1.61
Abbreviations: CI, confidence interval; COX-2, cyclooxygenase 2; NSAIDs, nonsteroidal antiinflammatory drugs; OR, odds ratio.
a Adjusted for age (continuous), sex, race (African-American or white), sampling probability, body mass index (weight (kg)/height (m)2; <25,
25–29.9, or 30) 1 year prior, ever use of calcium supplements in the past 5 years, physical activity 1 year prior (<1,882, 1,882–2,077, or 2,078
metabolic equivalent-minutes/day), total energy intake (<1,711, 1,711–2,413, or2,414 kcal/day), and dietary fat intake (<64, 64–97, or98 g/day).
b Continuing use in the year before diagnosis/interview.
c Among ever users, use at least 3 times per week for 3 months or more.
Table 2. Odds Ratios for the Association Between Use of Nonsteroidal Antiinflammatory Drugs and Distal Large Bowel Cancer, North Carolina
Colon Cancer Study II, 2001–2006
Cases Controls
ORa 95% CI Multivariable ORb 95% CI
No. % No. %
Never use (referent) 248 24.3 169 17.0 1.00 1.00
Ever use 772 75.7 827 83.0 0.67 0.54, 0.84 0.66 0.52, 0.83
Recent usec 688 67.5 775 77.8 0.64 0.51, 0.80 0.62 0.49, 0.79
Average monthly use in the past 5 years, no. of times
<15 446 43.7 415 41.7 0.73 0.57, 0.92 0.68 0.53, 0.88
15 326 32.0 412 41.4 0.61 0.48, 0.79 0.62 0.48, 0.81
Regular used of NSAIDs, by type
Over-the-counter aspirin 355 34.8 439 44.1 0.62 0.49, 0.80 0.62 0.48, 0.80
Over-the-counter nonaspirin NSAIDs 119 11.7 110 11.0 0.77 0.56, 1.08 0.72 0.51, 1.02
Prescription nonselective NSAIDs 66 6.5 81 8.1 0.59 0.40, 0.87 0.57 0.38, 0.85
Selective COX-2 inhibitors 87 8.5 135 13.6 0.48 0.34, 0.68 0.44 0.31, 0.63
Abbreviations: CI, confidence interval; COX-2, cyclooxygenase 2; NSAIDs, nonsteroidal antiinflammatory drugs; OR, odds ratio.
a Adjusted for age (continuous), sex, race (African-American or White), and sampling probability.
b Adjusted for age (continuous), sex, race (African-American or White), sampling probability, body mass index (weight (kg)/height (m)2; <25,
25–29.9, or 30) 1 year prior, ever use of calcium supplements in the past 5 years, physical activity 1 year prior (<1,882, 1,882–2,077, or 2,078
metabolic equivalent-minutes/day), total energy intake (<1,711, 1,711–2,413, or2,414 kcal/day), and dietary fat intake (<64, 64–97, or98 g/day).
c Continuing use in the year before diagnosis/interview.
d Use at least 3 times per week for 3 months or more.
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NSAIDs and distal large bowel cancer observed among
African Americans in the current study.
Alternatively, one might consider potential detection bias
through NSAID-induced endoscopic screening. While it is
possible that NSAIDs could cause lower gastrointestinal
bleeding, most side effects of NSAIDs are localized to the
upper gastrointestinal tract, such as the stomach and duode-
num, where cyclooxygenase 1 is constitutively expressed
(35): Upper gastrointestinal bleeding or pain alone rarely
leads to a colonoscopy. Martin et al. (36) previously exam-
ined the indications for colonoscopy in cases and controls
and found that the indications were similar in both races.
Lastly, the association we observed might result at least
partially from differences in the biology or etiology of distal
large bowel cancers between African Americans and whites.
Racial differences in the anatomic locationof colorectal cancer
have been noted, with African Americans beingmore likely to
develop proximal colorectal cancer than whites (16, 17).
In addition, several studies have reported on polymorphisms
of inflammation-related genes and their interactions with
NSAID use (37–39). Interestingly, the COX-2 V511A poly-
morphism, which is exclusively found in African Americans
(albeit at a low allele frequency (~5%)), appears to be inversely
associated with colorectal neoplasia like NSAIDs (37).
In the current study, NSAID use was more strongly asso-
ciated with rectal and rectosigmoid cancers than with sigmoid
cancer, which is consistent with several previous studies
(6, 13). On the other hand, some authors have reported more
pronounced associations between NSAIDs and colon cancer
than rectal cancer (7, 40), while others have reported similarly
strong associations with colon and rectal cancers (2, 4, 9, 12).
Different genetic aberrations have been associated with can-
cers arising at different subsites of the large bowel (15), sug-
gesting that the etiology of and risk factors for rectal cancer
might differ from those for colon cancer. Emerging data show
that the associations between NSAIDs and colorectal cancer
might also vary depending on tumor characteristics. Accord-
ing to a recent study, regular use of aspirin was inversely
associated with colorectal tumors characterized by modest-
to-strong COX-2 expression but was not associated with
tumors that hadweak or absent COX-2 expression (41). Given
that researchers have reported higher expression of COX-2 in
tumors originating in the rectum than in those originating
in the colon (42, 43), differences in COX-2 expression by
tumor location might result in differences in the magnitudes
of the associations with NSAIDs for rectal, rectosigmoid, and
sigmoid cancers.
Several potential limitations of our study should be
considered. First, we assessed NSAID exposure based on
self-report. Although NSAID use may be underreported by
participants (44), pharmacy records do not capture over-the-
counter NSAID use, which comprises the majority of
NSAID use. Second, although we evaluated and adjusted
for a range of potentially confounding factors, our effect
estimates for the association might have been biased by re-
sidual confounding by unknown factors related to the indi-
cation for NSAID use. However, to explain the association
observed, such a factor would have had to be strongly asso-
ciated with both NSAID use and distal large bowel cancer
and to be common in our study population (45).
Table 4. Odds Ratios for the Association Between Use of Nonsteroidal Antiinflammatory Drugs and Distal Large Bowel Cancer, by Tumor
Location, North Carolina Colon Cancer Study II, 2001–2006










No. % No. % No. %
Never use (referent) 97 20.7 1.00 47 28.0 1.00 104 27.2 1.00
Ever use 371 79.3 0.81 0.60, 1.09 121 72.0 0.50 0.33, 0.74 279 72.9 0.60 0.44, 0.81
Recent useb 338 72.2 0.79 0.58, 1.07 107 63.7 0.47 0.32, 0.71 242 63.2 0.55 0.41, 0.75
Average monthly use
in the past 5 years,
no. of times
<15 213 45.5 0.84 0.61, 1.15 76 45.2 0.55 0.36, 0.85 156 40.7 0.61 0.44, 0.85
15 158 33.8 0.78 0.56, 1.09 45 26.8 0.43 0.27, 0.69 123 32.1 0.58 0.41, 0.82
Regular usec of NSAIDs,
by type
Over-the-counter aspirin 187 39.9 0.83 0.60, 1.16 44 26.2 0.39 0.24, 0.62 124 32.4 0.54 0.38, 0.75
Over-the-counter,
nonaspirin NSAIDs
53 11.3 0.81 0.52, 1.26 17 10.1 0.45 0.24, 0.86 49 12.8 0.76 0.49, 1.17
Prescription nonselective
NSAIDs
33 7.1 0.71 0.43, 1.18 19 11.3 0.86 0.46, 1.60 14 3.7 0.30 0.15, 0.57
Selective COX-2 inhibitors 42 9.0 0.53 0.33, 0.83 18 10.7 0.48 0.26, 0.89 27 7.1 0.34 0.20, 0.57
Abbreviations: CI, confidence interval; COX-2, cyclooxygenase 2; NSAIDs, nonsteroidal antiinflammatory drugs; OR, odds ratio.
a Adjusted for age (continuous), sex, race (African-American or white), sampling probability, body mass index (weight (kg)/height (m)2; <25,
25–29.9, or 30) 1 year prior, ever use of calcium supplements in the past 5 years, physical activity 1 year prior (<1,882, 1,882–2,077, or 2,078
metabolic equivalent-minutes/day), total energy intake (<1,711, 1,711–2,413, or2,414 kcal/day), and dietary fat intake (<64, 64–97, or98 g/day).
b Continuing use in the year before diagnosis/interview.
c Among ever users, use at least 3 times per week for 3 months or more.
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Strengths of our study relative to previous research include
its exclusive focus on distal large bowel cancers. Despite
anatomic and biologic differences between proximal and dis-
tal colorectal cancer (14), there are relatively few epidemio-
logic studies of distal colorectal cancer. The current study was
specifically designed to identify risk factors for distal large
bowel cancer. Our study also included relatively large num-
bers of African-American cases and controls. Whereas Afri-
can Americans have the highest incidence of and mortality
from colorectal cancer among racial groups (46), etiologic
studies in this population have been few. Lastly, the preva-
lence of NSAID use in our study was generally comparable to
that in a study that used data from a national survey (47),
which enhances the potential generalizability of our results.
In our study, 83% of controls (85% of white controls and 74%
of African-American controls) reported ever use of NSAIDs
in the past 5 years. Similarly, in the Third National Health and
Nutrition Examination Survey (1988–1994), the overall prev-
alence of any analgesic use was approximately 73% in males
and 83% in females, with a lower prevalence of nonprescrip-
tion analgesic use among non-Hispanic blacks than among
non-Hispanic whites (47).
In conclusion, the current study suggests that in whites, an
inverse association with NSAIDs is not limited to colon
cancers but also appears to be present for distal large bowel
cancers, possibly with more potent effects for rectal and
rectosigmoid cancer than for sigmoid cancer. On the other
hand, the association between distal large bowel cancer and
NSAID use was not evident in African Americans in our
study. NSAIDs might not be effective in preventing all sub-
types of colorectal cancer or in preventing colorectal cancer
in all populations. Further studies should be directed to-
wards identifying characteristics of subgroups that might
most benefit from NSAIDs.
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Appendix Table. Names and Locations of Manufacturers of Brand-Name Products
Product Manufacturer Location
Advil Wyeth Consumer HealthCare Richmond, Virginia
Aleve Bayer Healthcare Morristown, New Jersey
Alka-Seltzer Bayer Healthcare Morristown, New Jersey
Anacin Insight Pharmaceuticals Corporation Langhorne, Pennsylvania
BC Powder GlaxoSmithKline Pharmaceuticals Memphis, Tennessee
Bromo Seltzer Tower Laboratories Ltd. Centerbrook, Connecticut
Bufferin Novartis Consumer Health, Inc. Parsippany, New Jersey
Celebrex Pfizer Inc. New York, New York
Daypro Pfizer Inc. New York, New York
Excedrin Novartis Consumer Health, Inc. Parsippany, New Jersey
Feldene Pfizer Inc. New York, New York
Goody’s Powder GlaxoSmithKline Consumer HealthCare Pittsburgh, Pennsylvania
Motrin McNeil Consumer Healthcare Langhorne, Pennsylvania
Naprosyn Hoffmann-La Roche Inc. Nutley, New Jersey
Stanback Headache Powders GlaxoSmithKline Consumer HealthCare Pittsburgh, Pennsylvania
Tylenol McNeil Consumer Healthcare Langhorne, Pennsylvania
Vioxx Merck & Company, Inc. Whitehouse Station, New Jersey
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